Search

Argenx SE

Avatud

SektorTervishoid

731.6 3.42

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

681.2

Max

742.8

Põhinäitajad

By Trading Economics

Sissetulek

455M

821M

Müük

1.5B

2.8B

P/E

Sektori keskmine

36.416

47.946

Aktsiakasum

7.32

Kasumimarginaal

29.79

Töötajad

1,863

EBITDA

70M

829M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

-2.07% downside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

22. okt 2026

Turustatistika

By TradingEconomics

Turukapital

3.6B

51B

Eelmine avamishind

728.18

Eelmine sulgemishind

731.6

Uudiste sentiment

By Acuity

51%

49%

248 / 340 Pingereas Healthcare

Argenx SE Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. okt 2026, 23:51 UTC

News

Brookdale Senior Living reported a 130 basis point increase in occupancy to 83.1% for Q3 2026, but shares declined in after-market hours.

8. okt 2026, 23:46 UTC

News

KKR shares are advancing as Refresco considers an IPO potentially valuing the firm at over $10 billion; KKR Capital Corp announced a $0.44 quarterly distribution.

8. okt 2026, 23:42 UTC

Social Media
News

Ginkgo Bioworks to provide in-kind access to its Boston lab for the National Science Foundation’s $1.5 billion X-Labs program supporting independent research teams.

8. okt 2026, 23:30 UTC

News

Pacira Biosciences shares declined in after-market hours following a downgrade by Jefferies to Hold, with a price target set at $36.

8. okt 2026, 23:30 UTC

News

Chipotle Mexican Grill Inc's stock advanced amid reports that Starbucks is considering a potential acquisition, with advisers enlisted for what could be a historic deal.

8. okt 2026, 23:30 UTC

News

Walt Disney Company is in talks with rival studios about its Infinity Vision format to compete with Imax, despite shares trading lower.

8. okt 2026, 23:20 UTC

News

Immersion Corp CEO Eric Singer acquired 41k shares for approximately $292.8K on October 7, according to a regulatory filing.

8. okt 2026, 23:15 UTC

News

Cleveland-Cliffs shares advanced in after-market trading as CEO Lourenco Goncalves discussed potential steelworker recalls tied to a Canada-U.S. trade deal.

8. okt 2026, 23:11 UTC

News

Abcellera Biologics to present Phase 1/2 data for investigational drug ABCL635 at The Menopause Society's Annual Meeting in October.

8. okt 2026, 23:10 UTC

News

Citigroup downgraded Universal Display Corp to Sell and lowered its price target to $71, contributing to investor caution ahead of earnings.

8. okt 2026, 23:10 UTC

News

JP Morgan maintains Underweight rating on Kennametal Inc and lowers price target to $30, contributing to a decline in the stock during after-market hours.

8. okt 2026, 23:10 UTC

News

Barclays initiates Equalweight coverage with $554 target.

8. okt 2026, 23:05 UTC

News

Boeing Co shares gained in after-market hours after Barclays initiated coverage with an Overweight rating and a price target of $300.

8. okt 2026, 23:05 UTC

News
Correlated Moves

HubSpot Inc. declines in after-market trading following a downgrade from JP Morgan, which lowered its rating to Neutral and price target to $240.

8. okt 2026, 23:05 UTC

News

Barclays initiates coverage on Joby Aviation with an Underweight rating and a price target of $4.00, contributing to recent declines in after-market trading.

8. okt 2026, 23:05 UTC

News

USD/CZK declines modestly following U.S. jobless claims data showing initial claims fell to 197k, indicating ongoing labor market strength amid broader economic concerns.

8. okt 2026, 23:01 UTC

Social Media
News
Event

Park Aerospace Corp reported second-quarter net sales of $20.79 million and net earnings of $4.53 million, exceeding expectations amid strong demand in aerospace sectors.

8. okt 2026, 23:01 UTC

News

Over 69% of Medicare Advantage members in high-rated plans for 2027

8. okt 2026, 23:01 UTC

Social Media
News

Alignment Healthcare's stock declined sharply after a downgrade of its largest California contract's Medicare Advantage Star Rating from 4 stars to 3.5 stars.

8. okt 2026, 23:01 UTC

News

JP Morgan maintains Neutral rating on Deere & Co, raises price target to $625, reflecting a cautious outlook on the company's performance.

8. okt 2026, 23:01 UTC

News

Moomoo launches 24/7 account deposits via Apple Pay and Google Pay through a partnership with Visa and Checkout.com to enhance user funding capabilities.

8. okt 2026, 23:01 UTC

News

Citigroup downgraded Xerox Holdings Corp to Sell and lowered its price target to $2.50, citing concerns over performance and market position.

8. okt 2026, 23:01 UTC

News
Social Media
Correlated Moves

Verizon shares fell sharply in after-hours trading, attributed to competitive pressures from SpaceX's spectrum license acquisition and AT&T's notable drop.

8. okt 2026, 23:01 UTC

Social Media
News

American Express faces regulatory scrutiny and agrees to a $350 million penalty for anti-money laundering deficiencies related to $13 billion in suspected activity.

8. okt 2026, 23:01 UTC

News

USD/ZAR declines as U.S. jobless claims show a four-week average of 198k, slightly down from 200.5k.

8. okt 2026, 23:01 UTC

Social Media
News

RTX Corp awarded a five-year contract worth up to $6.3 billion for Standard Missile-3 Block IB interceptors, announced by Raytheon.

8. okt 2026, 23:01 UTC

News

Humana's largest Medicare Advantage contract improved to 4 stars in the 2027 ratings, reinstating eligibility for federal quality bonus payments.

8. okt 2026, 23:01 UTC

News

DICK'S Sporting Goods faces a class action lawsuit for failing to disclose material information, with Kahn Swick & Foti, LLC urging affected shareholders to file by November 3, 2026.

8. okt 2026, 23:00 UTC

News

Citigroup maintains a Buy rating on Arista Networks and raises its price target to $248, according to a report published today.

8. okt 2026, 22:50 UTC

Social Media
News

Starbucks explored a potential acquisition of Chipotle, valued at $41 billion, but analysts express skepticism about the strategic rationale amid ongoing turnaround efforts.

Võrdlus sarnastega

Hinnamuutus

Argenx SE Prognoos

Hinnasiht

By TipRanks

-2.07% langus

12 kuu keskmine prognoos

Keskmine 438.33 EUR  -2.07%

Kõrge 545 EUR

Madal 223 EUR

Põhineb 6 Wall Streeti analüütiku instrumendi Argenx SE 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

5

Osta

0

Hoia

1

Müü

Sentiment

By Acuity

248 / 340 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.